相关实验视频

Updated: Jul 18, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

在B细胞前体急性淋巴细胞白血病中使用伊诺图祖马布 (inotuzumab ozogamicin):疗效,毒性和实际考虑

Jeremy D Rubinstein^1,2, Maureen M O'Brien^1,2

¹Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States.

Frontiers in immunology

|August 21, 2023

概括

伊诺图祖马布 (ozogamicin) 在复发的B细胞前体急性淋巴细胞白血病中显示出有效性. 由于潜在的毒性,如阴影阻塞综合征和B细胞无形成症,仔细考虑后续疗法至关重要.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
药理学药理学是指药理学的学科.

背景情况:

伊诺图祖马布奥佐加米辛 (InO) 是一种针对CD22.22的抗体药物联合体.
它在复发/耐药B细胞前体急性淋巴细胞白血病 (BCP-ALL) 中表现出显著的活性.

研究的目的:

审查关于InO的当前数据,重点关注儿科试验.
探索未来的方向,包括组合疗法.

主要方法:

对InO.O.现有的临床试验数据的审查.
对毒性概况和耐药性机制的分析.

主要成果:

在成人和儿科中,InO对复发性/耐药性BCP-ALL具有活性.
关键的毒性包括鼻状阻塞综合征 (SOS) 和B细胞无形成症.
随后的治疗决策 (HSCT,CAR-T) 必须考虑到INO相关的风险.

结论:

InO是R/R BCP-ALL的重要治疗选择.
管理毒性和计划后续治疗对于最佳结果至关重要.
对组合疗法和抵抗机制的进一步研究是有必要的.

关键词:

在 BCP-ALL 中,在CD2222中,我们可以看到CD22.急性淋巴细胞白血病急性淋巴细胞白血病抗体药物联合体的抗体.伊诺图祖马布 (inotuzumab) 是一种奥佐加米的药物.复发/耐药性复发/耐药性阴侧阻塞综合征是什么?

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...